Clinical Trials
26
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (25 trials with phase data)• Click on a phase to view related trials
Immunotherapy Study of Evofosfamide in Combination With Ipilimumab
- Conditions
- Pancreatic CancerMelanomaSquamous Cell Carcinoma of the Head and NeckProstate Cancer
- Interventions
- First Posted Date
- 2017-03-31
- Last Posted Date
- 2017-10-30
- Lead Sponsor
- Threshold Pharmaceuticals
- Target Recruit Count
- 69
- Registration Number
- NCT03098160
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Drug: TH-302 combination with pemetrexedDrug: Matched placebo in combination with pemetrexed
- First Posted Date
- 2014-03-21
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- ImmunoGenesis
- Target Recruit Count
- 265
- Registration Number
- NCT02093962
- Locations
- 🇺🇸
UAB Cancer Center, Birmingham, Alabama, United States
🇺🇸Ironwood Cancer and Research Centers, Chandler, Arizona, United States
🇺🇸California Cancer Center, Encinitas, California, United States
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- ImmunoGenesis
- Target Recruit Count
- 19
- Registration Number
- NCT02047500
- Locations
- 🇺🇸
Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors
- First Posted Date
- 2013-12-24
- Last Posted Date
- 2016-06-02
- Lead Sponsor
- Threshold Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT02020226
- Locations
- 🇺🇸
The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Yuma Regional Cancer Center, Yuma, Arizona, United States
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
- First Posted Date
- 2013-05-29
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- ImmunoGenesis
- Target Recruit Count
- 11
- Registration Number
- NCT01864538
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸UCLA, Los Angeles, California, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
- Prev
- 1
- 2
- 3
- 4
- Next